Stoke Therapeutics (NASDAQ:STOK) Director Edward Md Kaye Sells 12,567 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Edward Md Kaye sold 12,567 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total value of $402,521.01. Following the completion of the sale, the director directly owned 124,557 shares of the company’s stock, valued at $3,989,560.71. The trade was a 9.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Stoke Therapeutics Stock Performance

STOK stock opened at $32.14 on Wednesday. The stock’s 50 day simple moving average is $30.81 and its 200 day simple moving average is $32.21. The company has a market cap of $2.07 billion, a P/E ratio of -9.62 and a beta of 1.20. Stoke Therapeutics, Inc. has a fifty-two week low of $18.00 and a fifty-two week high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. The firm had revenue of $9.32 million during the quarter, compared to analyst estimates of $4.89 million. Equities analysts predict that Stoke Therapeutics, Inc. will post -3.5 earnings per share for the current year.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds have recently bought and sold shares of STOK. Kestra Advisory Services LLC purchased a new stake in shares of Stoke Therapeutics in the fourth quarter valued at about $26,000. Quantbot Technologies LP bought a new stake in Stoke Therapeutics in the 2nd quarter worth about $34,000. KBC Group NV bought a new stake in Stoke Therapeutics in the 1st quarter worth about $36,000. Harbour Investments Inc. increased its stake in Stoke Therapeutics by 312.9% in the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after buying an additional 898 shares during the last quarter. Finally, Western Wealth Management LLC purchased a new position in shares of Stoke Therapeutics in the 1st quarter worth approximately $55,000.

Analyst Ratings Changes

A number of research analysts have weighed in on STOK shares. Canaccord Genuity Group dropped their price objective on shares of Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating on the stock in a research note on Tuesday, August 4th. Weiss Ratings reissued a “sell (d)” rating on shares of Stoke Therapeutics in a research report on Friday, August 7th. Guggenheim reaffirmed a “buy” rating and issued a $60.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. Wedbush raised their price target on shares of Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a research report on Tuesday, August 4th. Finally, Chardan Capital reissued a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, August 4th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.00.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.